Eleftherios Mylonakis Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Researcher

John Brown University

faculty

93 h-index 568 pubs 31,556 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Eleftherios Mylonakis is an actively publishing faculty member at John Brown University whose research spans both infectious disease and liver disease. His work addresses antifungal resistance and susceptibility, along with fungal infections generally. Mylonakis also studies antimicrobial resistance in Staphylococcus and bacterial identification methods. Furthermore, he has contributed to COVID-19 clinical research, including interventional trials of antiviral treatments for hospitalized patients. His work includes epidemiological studies of steatotic liver disease in the United States, as well as research into the prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV.

Metrics

  • h-index: 93
  • Publications: 568
  • Citations: 31,556

Selected Publications

  • Resveratrol-coated gold nanorods produced by green synthesis with activity against <i>Candida albicans</i> (2024) DOI
  • Treatment of Macrolide-resistant Mycoplasma pneumoniae Pneumonia in Children: A Meta-analysis of Macrolides Versus Tetracyclines (2024) DOI
  • Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis (2024) DOI
  • Thematic analysis to explore patients’ experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives (2024) DOI
  • Cumulative incidence and mortality rate of cardiovascular complications due to laboratory‐confirmed influenza virus infection: A systematic review and meta‐analysis (2023) DOI
  • A Methylazanediyl Bisacetamide Derivative Sensitizes <i>Staphylococcus aureus</i> Persisters to a Combination of Gentamicin And Daptomycin (2023) DOI
  • Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020 (2023) DOI
  • Gold complex compounds that inhibit drug-resistant Staphylococcus aureus by targeting thioredoxin reductase (2023) DOI
  • New-Onset Diabetes After COVID-19 (2023) DOI
  • Antimicrobial Peptides and Small Molecules Targeting the Cell Membrane of Staphylococcus aureus (2023) DOI
  • Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers (2023) DOI
  • Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis (2023) DOI
  • Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study (2023) DOI
  • SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine — Ohio and Rhode Island, September–November 2022 (2023) DOI
  • Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis (2023) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics